We are live on ! Find out more
NAMS icon

NewAmsterdam Pharma
NAMS

131 hedge funds and large institutions have $2.11B invested in NewAmsterdam Pharma in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 30

30% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 20

4% more funds holding

Funds holding: 126 → 131 (+5)

2.41% more ownership

Funds ownership: 101.24% → 103.65% (+2.4%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

8% less capital invested

Capital invested by funds: $2.28B → $2.11B (-$171M)

72% less call options, than puts

Call options by funds: $1.18M | Put options by funds: $4.16M

Holders
131
Holders Change
+5
Holders Change %
+3.97%
% of All Funds
1.72%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
26
Increased
58
Reduced
30
Closed
20
Calls
$1.18M
Puts
$4.16M
Net Calls
-$2.98M
Net Calls Change
-$6.07M

Top Buyers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
+$29M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$19.4M
3
DM
Deerfield Management
New York
+$18.5M
4
MC
Maverick Capital
Texas
+$17.9M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$17.2M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$18.7M
2
SL
Siren LLC
Connecticut
-$13.1M
3
CAM
Cormorant Asset Management
Massachusetts
-$11.9M
4
WP
Woodline Partners
California
-$9.94M
5
Citadel Advisors
Citadel Advisors
Florida
-$6.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
TWD
126
True Wealth Design
Ohio
$381 +$347 +19 +950%
KG
127
Kilter Group
New York
$182 +$182 +10 New
EWA
128
EverSource Wealth Advisors
Alabama
$145 +$109 +6 +300%
IA
129
IFP Advisors
Florida
$54 +$36 +2 +200%
EP
130
Essential Partners
California
$36 +$36 +2 New
DCM
131
Dupont Capital Management
Delaware
$18 – – –
CCM
132
Cutter Capital Management
New York
– -$4.53M -221,152 Closed
PHP
133
Parkman Healthcare Partners
Connecticut
– -$2.07M -100,955 Closed
APM
134
Avidity Partners Management
Texas
– -$1.39M -68,000 Closed
TI
135
Trexquant Investment
Connecticut
– -$1.35M -66,102 Closed
ECM
136
ExodusPoint Capital Management
New York
– -$1.22M -59,644 Closed
BI
137
BVF Inc
California
– -$1.21M -59,065 Closed
OAC
138
OMERS Administration Corp
Ontario, Canada
– -$772K -37,700 Closed
SSA
139
Schonfeld Strategic Advisors
New York
– -$685K -33,457 Closed
GGHC
140
Gilder Gagnon Howe & Co
New York
– -$605K -29,569 Closed
GCP
141
GSA Capital Partners
United Kingdom
– -$458K -22,358 Closed
BPC
142
Bryce Point Capital
New York
– -$438K -19,653 Closed
HWM
143
HB Wealth Management
Georgia
– -$230K -11,247 Closed
KeyBank National Association
144
KeyBank National Association
Ohio
– -$204K -9,983 Closed
SG Americas Securities
145
SG Americas Securities
New York
– -$116K -5,659 Closed
PA
146
PSI Advisors
Florida
– -$10.2K -500 Closed
CA
147
Continuum Advisory
Idaho
– -$3.15K -154 Closed
CCM
148
Coldstream Capital Management
Washington
– -$492 -24 Closed
PS
149
Principal Securities
Iowa
– -$334 -13 Closed
GI
150
GAMMA Investing
California
– -$143 -7 Closed
3 4 5
6
7

NAMS Hedge Fund Activity: Q2 2025 in Review

131 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma (NAMS) for Q2 2025, worth a combined $2.11B — down 7.5% from $2.28B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new NAMS positions and 20 closed out — a net gain of 6 holders — while 58 added to existing stakes and 30 trimmed.

The largest buyer was Capital World Investors, adding an estimated $29M. The largest seller was Jennison Associates, cutting an estimated $18.7M.

  • 131 institutional investors held NewAmsterdam Pharma (NAMS) as of Q2 2025, up from 126 in Q1 2025.
  • Funds reported $2.11B of NewAmsterdam Pharma stock for Q2 2025, down 7.5% quarter-over-quarter.
  • 26 funds opened new NewAmsterdam Pharma positions in Q2 2025 and 20 closed out, a net change of +6 holders.
  • The largest NewAmsterdam Pharma buyer in Q2 2025 was Capital World Investors, an estimated $29M added.
  • The largest NewAmsterdam Pharma seller in Q2 2025 was Jennison Associates, an estimated $18.7M sold.

Based on aggregated 13F filings for Q2 2025.